Taiwan
Key Insights
- 1
No psychedelic therapy is legally approved for patients in Taiwan; access is limited to specialist use of ketamine and esketamine under standard medical prescribing.
- 2
Blossom counts 7 trials in Taiwan, all inactive; ketamine, esketamine and placebo dominate, with one research organisation.
- 3
A 2017 Taiwanese trial was the first to report dose-related antidepressant effects of R/S-ketamine in a genotyped Chinese TRD cohort.
- 4
Momentum sits with Taipei Veterans General Hospital and National Yang Ming Chiao Tung University, where 2024–2025 ketamine studies continue to sharpen depression and suicidality data.
Reimbursed Care Access
Psychedelic and entheogenic compounds in Taiwan are, as a rule, scheduled and tightly controlled under national narcotics/controlled‑drugs legislation; most classical psychedelics (psilocybin, MDMA, DMT family, mescaline, ibogaine, 2C‑X, ayahuasca preparations) have no authorized medical use outside approved clinical research and are treated as illicit. Ketamine is an accepted medical anesthetic and is used clinically (and appears in addiction / forensic policing statistics), but non‑medical possession and diversion are criminalized; dedicated esketamine (Spravato®) regulatory status in Taiwan is not documented in public TFDA approvals as of Feb 20, 2026. [https://www.mohw.gov.tw/cp-3163-28284-1.html|Ministry of Health and Welfare MOHW overview] [https://mohw.gov.tw/fp-16-21181-1.html|MOHW: new psychoactive & controlled substances advisory].
Quick Indicators
Organizations
1Clinical Trials
Active and completed clinical trials investigating psychedelic-assisted therapies in Taiwan.